- Home
- ADAP vs ICCM Comparison
ADAP vs ICCM Comparison
Compare ADAP & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- ICCM
- Stock Information
- Founded
- ADAP 2008
- ICCM 2006
- Country
- ADAP United Kingdom
- ICCM Israel
- Employees
- ADAP N/A
- ICCM N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- ADAP Health Care
- ICCM
- Exchange
- ADAP Nasdaq
- ICCM Nasdaq
- Market Cap
- ADAP 71.6M
- ICCM 74.7M
- IPO Year
- ADAP 2015
- ICCM N/A
- Fundamental
- Price
- ADAP $0.21
- ICCM $1.11
- Analyst Decision
- ADAP Strong Buy
- ICCM Strong Buy
- Analyst Count
- ADAP 5
- ICCM 1
- Target Price
- ADAP $1.93
- ICCM $2.50
- AVG Volume (30 Days)
- ADAP 2.4M
- ICCM 363.9K
- Earning Date
- ADAP 03-20-2025
- ICCM 03-27-2025
- Dividend Yield
- ADAP N/A
- ICCM N/A
- EPS Growth
- ADAP N/A
- ICCM N/A
- EPS
- ADAP N/A
- ICCM N/A
- Revenue
- ADAP $178,032,000.00
- ICCM $3,291,000.00
- Revenue This Year
- ADAP N/A
- ICCM $75.63
- Revenue Next Year
- ADAP $56.87
- ICCM $69.36
- P/E Ratio
- ADAP N/A
- ICCM N/A
- Revenue Growth
- ADAP 195.34
- ICCM 1.92
- 52 Week Low
- ADAP $0.20
- ICCM $0.48
- 52 Week High
- ADAP $1.55
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- ADAP 14.09
- ICCM 35.03
- Support Level
- ADAP $0.26
- ICCM $1.04
- Resistance Level
- ADAP $0.47
- ICCM $1.25
- Average True Range (ATR)
- ADAP 0.04
- ICCM 0.09
- MACD
- ADAP -0.02
- ICCM -0.04
- Stochastic Oscillator
- ADAP 1.23
- ICCM 14.29
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.